What is the share price of Sanofi India Ltd (SANOFI) today?
The share price of SANOFI as on 4th November 2025 is ₹4750.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sanofi India Ltd (SANOFI) share?
The past returns of Sanofi India Ltd (SANOFI) share are- Past 1 week: 1.75%
- Past 1 month: 0.88%
- Past 3 months: -12.17%
- Past 6 months: -19.02%
- Past 1 year: -28.66%
- Past 3 years: 36.28%
- Past 5 years: -8.44%
What are the peers or stocks similar to Sanofi India Ltd (SANOFI)?
The peers or stocks similar to Sanofi India Ltd (SANOFI) include:What is the dividend yield % of Sanofi India Ltd (SANOFI) share?
The current dividend yield of Sanofi India Ltd (SANOFI) is 2.46.What is the market cap of Sanofi India Ltd (SANOFI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sanofi India Ltd (SANOFI) is ₹10941.62 Cr as of 4th November 2025.What is the 52 week high and low of Sanofi India Ltd (SANOFI) share?
The 52-week high of Sanofi India Ltd (SANOFI) is ₹6822.65 and the 52-week low is ₹4623.50.What is the PE and PB ratio of Sanofi India Ltd (SANOFI) stock?
The P/E (price-to-earnings) ratio of Sanofi India Ltd (SANOFI) is 26.47. The P/B (price-to-book) ratio is 12.71.Which sector does Sanofi India Ltd (SANOFI) belong to?
Sanofi India Ltd (SANOFI) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sanofi India Ltd (SANOFI) shares?
You can directly buy Sanofi India Ltd (SANOFI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sanofi India Ltd
SANOFI Share Price
SANOFI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SANOFI Performance & Key Metrics
SANOFI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.71 | 12.71 | 2.46% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.13 | 5.85 | 0.58% |
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
SANOFI Company Profile
Sanofi India Limited is engaged in the manufacture and sale of pharmaceutical products.
SANOFI Sentiment Analysis
SANOFI Sentiment Analysis
SANOFI Stock Summary · May 2024
In Q1 2024, Sanofi India faced challenges from the NLEM price decrease, resulting in a profit decline, yet demonstrated resilience with a 3% growth in domestic sales when excluding this impact. The company is strategically expanding its diabetes portfolio, notably with the launch of Soliqua, while leveraging local partnerships to enhance distribution in underserved markets. This approach, coupled with a focus on operational efficiency and localized innovation, positions Sanofi to capture new patient demographics and strengthen its market presence. Additionally, the transition towards a Fast-Moving Consumer Healthcare organization reflects a commitment to digital engagement and e-commerce growth, setting the stage for future product launches and sustained profitability. Overall, the sentiment remains optimistic as Sanofi navigates these dynamics while maintaining a strong foundation in the insulin market.
SANOFI Stock Growth Drivers
SANOFI Stock Growth Drivers
6Expansion of Diabetes Portfolio
Sanofi India has made significant strides in expanding its diabetes product offerings, particularly with the
Strategic Partnerships for Growth
Sanofi India has established strategic partnerships with local companies to enhance the distribution and promotion
SANOFI Stock Challenges
SANOFI Stock Challenges
3Declining Profitability
Sanofi India Limited reported a profit before exceptional items and tax of INR 215 crores
Reduction in Workforce
The company experienced a significant reduction in employee count, decreasing from approximately 2,600 in fiscal
SANOFI Forecast
SANOFI Forecasts
Price
Revenue
Earnings
SANOFI Share Price Forecast
SANOFI Share Price Forecast
All values in ₹
All values in ₹
SANOFI Company Revenue Forecast
SANOFI Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
SANOFI Stock EPS (Earnings Per Share) Forecast
SANOFI Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
SANOFI
SANOFI
Income
Balance Sheet
Cash Flow
SANOFI Income Statement
SANOFI Income Statement
| Financial Year | FY 2023 | FY 2024 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 2,313.40 | 2,129.30 | 1,963.30 | |||
| Raw Materials | 1,237.20 | 919.10 | 1,440.50 | |||
| Power & Fuel Cost | 8.40 | 11.60 | ||||
| Employee Cost | 280.70 | 240.20 | ||||
| Selling & Administrative Expenses | 192.70 | 212.10 | ||||
| Operating & Other expenses | -210.60 | 177.10 | ||||
| EBITDA | 805.00 | 569.20 | 522.80 | |||
| Depreciation/Amortization | 36.50 | 36.70 | 37.40 | |||
| PBIT | 768.50 | 532.50 | 485.40 | |||
| Interest & Other Items | 1.70 | 1.50 | 1.50 | |||
| PBT | 766.80 | 531.00 | 483.90 | |||
| Taxes & Other Items | 163.90 | 117.70 | 127.60 | |||
| Net Income | 602.90 | 413.30 | 356.30 | |||
| EPS | 261.78 | 179.46 | 154.71 | |||
| DPS | 167.00 | 117.00 | 117.00 | |||
| Payout ratio | 0.64 | 0.65 | 0.76 |
SANOFI Company Updates
Investor Presentation
SANOFI Stock Peers
SANOFI Past Performance & Peer Comparison
SANOFI Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sanofi India Ltd | 26.47 | 12.71 | 2.46% |
| Sun Pharmaceutical Industries Ltd | 37.10 | 5.59 | 0.95% |
| Cipla Ltd | 23.03 | 3.88 | 1.06% |
| Torrent Pharmaceuticals Ltd | 63.31 | 15.94 | 0.90% |
SANOFI Stock Price Comparison
Compare SANOFI with any stock or ETFSANOFI Holdings
SANOFI Shareholdings
SANOFI Promoter Holdings Trend
SANOFI Promoter Holdings Trend
SANOFI Institutional Holdings Trend
SANOFI Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
SANOFI Shareholding Pattern
SANOFI Shareholding Pattern
SANOFI Shareholding History
SANOFI Shareholding History
Mutual Funds Invested in SANOFI
Mutual Funds Invested in SANOFI
No mutual funds holding trends are available
Top 5 Mutual Funds holding Sanofi India Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4264% | Percentage of the fund’s portfolio invested in the stock 0.71% | Change in the portfolio weight of the stock over the last 3 months -0.45% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/69 (-2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0620% | Percentage of the fund’s portfolio invested in the stock 0.25% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 74/97 (-10) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.0569% | Percentage of the fund’s portfolio invested in the stock 0.39% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 40/101 (-5) |
Compare 3-month MF holding change on Screener
smallcases containing SANOFI stock
smallcases containing SANOFI stock
Looks like this stock is not in any smallcase yet.
SANOFI Events
SANOFI Events
SANOFI Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
SANOFI Dividend Trend
No dividend trend available
SANOFI Upcoming Dividends
SANOFI Upcoming Dividends
Cash Dividend
Ex DateEx DateNov 7, 2025
Dividend/Share
₹75.00
Ex DateEx Date
Nov 7, 2025
SANOFI Past Dividends
SANOFI Past Dividends
Cash Dividend
Ex DateEx DateApr 25, 2025
Dividend/Share
₹117.00
Ex DateEx Date
Apr 25, 2025
Cash Dividend
Ex DateEx DateMay 3, 2024
Dividend/Share
₹117.00
Ex DateEx Date
May 3, 2024
Cash Dividend
Ex DateEx DateMar 7, 2024
Dividend/Share
₹50.00
Ex DateEx Date
Mar 7, 2024
Cash Dividend
Ex DateEx DateApr 28, 2023
Dividend/Share
₹194.00
Ex DateEx Date
Apr 28, 2023
Cash Dividend
Ex DateEx DateApr 28, 2023
Dividend/Share
₹183.00
Ex DateEx Date
Apr 28, 2023
SANOFI Stock News & Opinions
SANOFI Stock News & Opinions
Net profit of Sanofi India declined 7.54% to Rs 76.00 crore in the quarter ended September 2025 as against Rs 82.20 crore during the previous quarter ended September 2024. Sales declined 9.27% to Rs 475.40 crore in the quarter ended September 2025 as against Rs 524.00 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales475.40524.00 -9 OPM %28.2322.84 - PBDT138.70121.60 14 PBT129.60112.60 15 NP76.0082.20 -8 Powered by Capital Market - Live
Sanofi India announced that the Board of Directors of the Company at its meeting held on 29 October 2025, has recommended a Interim Dividend of Rs.75 per share (i.e.750%), subject to the approval of the shareholders.Powered by Capital Market - Live
The Board of Sanofi India at its meeting held on 27 October 2025 has approved the following- Appointment of Deepak Arora (DIN: 07495638) as an Additional Director of the Company with effect from 27 October 2025 and as a Managing Director (Key Managerial Personnel) of the Company for a term of 3 (three) years effective from 27 October 2025. Stepping down of Rachid Ayari as Interim Managing Director of the Company with effect from close of 26 October 2025. However, Rachid Ayari would continue to serve the Company in his role as Whole time Director and Chief Financial Officer of the Company.Powered by Capital Market - Live
Sanofi India will hold a meeting of the Board of Directors of the Company on 29 October 2025.Powered by Capital Market - Live
Sanofi India announced that Surabhi Kaul, People Director - SEA&I, will cease to be a Senior Management Personnel (SMP) of the Company effective from the close of business on 14 August 2025, in view of her movement to another role within the Sanofi group. Powered by Capital Market - Live
Net profit of Sanofi India declined 32.79% to Rs 69.50 crore in the quarter ended June 2025 as against Rs 103.40 crore during the previous quarter ended June 2024. Sales declined 12.34% to Rs 406.30 crore in the quarter ended June 2025 as against Rs 463.50 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales406.30463.50 -12 OPM %23.3624.96 - PBDT103.20120.10 -14 PBT94.10111.10 -15 NP69.50103.40 -33 Powered by Capital Market - Live
Sanofi India will hold a meeting of the Board of Directors of the Company on 31 July 2025.Powered by Capital Market - Live
Net profit of Sanofi India declined 12.52% to Rs 119.50 crore in the quarter ended March 2025 as against Rs 136.60 crore during the previous quarter ended March 2024. Sales rose 4.91% to Rs 535.90 crore in the quarter ended March 2025 as against Rs 510.80 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales535.90510.80 5 OPM %32.0826.84 - PBDT174.90140.30 25 PBT165.30131.20 26 NP119.50136.60 -13 Powered by Capital Market - Live
Sanofi India will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live
The board of directors accepted Hrosz's resignation during a meeting held on 9 April and expressed appreciation for his significant contributions during his tenure. Hrosz will cease to be a key managerial personnel, senior management personnel, and a member of board committees at the close of business hours on 30 April 2025. Further, the board approved Hrosz's appointment as an additional non-executive director effective 1 May 2025, subject to shareholder approval, upon the recommendation of the nomination and remuneration committee (NRC). Sanofi India is among the leading multinational companies in the Indian pharmaceutical market. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, the central nervous system, and antihistamines. The company's consolidated net profit declined 33.7% to Rs 91.30 crore in Q4 FY25 as against Rs 137.70 crore reported in Q4 FY24. Total revenue from operations grew by 9.7% year on year (YoY) to Rs 514.90 crore in the quarter ended 31 March 2024. Shares of Sanofi India rose 0.83% to Rs 6,100 on the BSE. Powered by Capital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant